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Summary. The emergency caused by Covid-19 pandemic raised interest in studying lifestyles and comorbidi-
ties as important determinants of poor Covid-19 prognosis. Data on tobacco smoking, alcohol consumption 
and obesity are still limited, while no data are available on the role of e-cigarettes and heated tobacco products 
(HTP). To clarify the role of tobacco smoking and other lifestyle habits on COVID-19 severity and progres-
sion, we designed a longitudinal observational study titled COvid19 and SMOking in ITaly (COSMO-IT). 
About 30 Italian hospitals in North, Centre and South of Italy joined the study. Its main aims are: 1) to 
quantify the role of tobacco smoking and smoking cessation on the severity and progression of COVID-19 
in hospitalized patients; 2) to compare smoking prevalence and severity of the disease in relation to smoking 
in hospitalized COVID-19 patients versus patients treated at home; 3) to quantify the association between 
other lifestyle factors, such as e-cigarette and HTP use, alcohol and obesity and the risk of unfavourable 
COVID-19 outcomes. Socio-demographic, lifestyle and medical history information will be gathered for 
around 3000 hospitalized and 700-1000 home-isolated, laboratory-confirmed, COVID-19 patients. Given 
the current absence of a vaccine against SARS-COV-2 and the lack of a specific treatment for  COVID-19, 
prevention strategies are of extreme importance. This project, designed to highly contribute to the interna-
tional scientific debate on the role of avoidable lifestyle habits on COVID-19 severity, will provide valuable 
epidemiological data in order to support important recommendations to prevent COVID-19 incidence, pro-
gression and mortality.
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Introduction
Italy was the first European country to be affected 
by COVID-19, an infectious disease caused by a new 
coronavirus named SARS-COV-2 (1). The infection 
started at the end of January 2020, rapidly spread, par-
ticularly in northern Italy, and almost 250,000 con-
firmed cases and more than 35,000 deaths (about 14% 
of all confirmed cases) occurred so far ( July 28th).
Preliminary data showed that the main deter-
minants of a poor prognosis of COVID19 were male 
sex, advanced age and previous comorbidities, most of 
which are tobacco-related diseases (2,3). In Italy, le-
thality rates vary between less than 1% for confirmed 
patients under age 50 years to over 25% for those aged 
80 years or more (4). The risk of mortality in infected 
people increased with the increase in the number of 
concomitant chronic diseases, including in particular 
cardiovascular diseases (hypertension, ischemic heart 
disease, atrial fibrillation), diabetes, cancer, renal fail-
ure, and chronic obstructive pulmonary disease (2, 5).
Tobacco smoking appears to be an important 
avoidable risk factor for poor prognosis (2, 5-9), but its 
role on the development, progression, and prognosis 
of COVID-19 has not yet been fully clarified. Some 
studies found that, among patients with COVID-19, 
smokers had a substantial increased risk of major unfa-
vourable health outcomes, including hospitalization in 
an intensive care unit, need for mechanical ventilation, 
or death (2, 5, 7-8, 10). Most of these studies, however, 
were based on relatively small samples or did not adjust 
for potential confounding factors. The role of smoking 
cessation on COVID-19 prognosis is also unclear, as 
former smokers in Chinese studies appeared to have 
a similar increased risk as current smokers. The role 
of e-cigarettes and heated tobacco products (HTP) on 
COVID-19 incidence and severity has not yet been 
investigated, but these products are likely to be associ-
ated with a poorer prognosis too (11).
Other lifestyle habits could be associated with 
COVID-19 progression and prognosis (12). 
A French study showed a high frequency of obe-
sity among patients admitted to intensive care units, 
with the disease severity increasing with increasing 
body mass index (13). No data on alcohol consump-
tion and unfavourable progression of COVID-19 are 
currently available, but a direct association is possible 
due to alcohol-induced damage to the upper respira-
tory and digestive tract (14) and its weakening of the 
immune system, with an increasing risk of respiratory 
and pulmonary viral infections (15).
In addition, potential lifestyle factors associated 
with the setting where patients are treated, hospital 
versus home, have not yet been studied. Patients iso-
lated at home, presumably with a less severe disease, 
might have different lifestyle habits compared to hos-
pitalized ones. However, no data comparing lifestyle 
in the two settings of patients are currently available, 
and their ascertainment could explain some unresolved 
issues.
Further data from large, well-conducted studies, 
whose designs allow adjustment at least for age, sex 
and concomitant diseases are required.
Given the current absence of a vaccine against 
SARS-COV-2 and the lack of a specific treatment for 
COVID-19, to clearly elucidate if smoking, the most 
important avoidable risk factor, may have an important 
role on COVID-19 severity and prognosis, is of great 
importance for prevention strategies. 
Thus, thanks to the close collaboration between 
the Italian Society of Tobaccology (SITAB), the 
Mario Negri Institute of Pharmacological Research 
(IRFMN) of Milan, the Institute for the Network of 
Prevention and Oncology Studies (ISPRO), the Sa-
pienza University of Rome, and the request for origi-
nal Italian data on these issues by the World Health 
Organization (WHO), the idea of organizing a multi-
centric study was born.
This study, with the acronym COSMO-IT 
(COvid19 and SMOking in ITaly), will enroll con-
firmed Italian cases of COVID-19 and its protocol is 
here presented.
Research Aims 
The COSMO-IT study has three main objectives:
1)  to quantify the role of tobacco smoking and 
smoking cessation on the severity and progres-
sion of COVID-19 in hospitalized patients;
2)  to compare smoking prevalence and sever-
ity of the disease in relation to smoking in 
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hospitalized COVID-19 patients versus pa-
tients treated at home;
3)  to quantify the association between other life-
style factors, such as e-cigarette and HTP use, 
alcohol and obesity and the risk of an unfa-
vorable outcome of COVID-19.
Materials and Methods
Study Design
COSMO-IT is a longitudinal observational study 
of confirmed COVID-19 patients. It will be prospec-
tive, for new patients, and retrospective for previously 
hospitalized or isolated patients.
Setting 
About 30 hospitals in North, Centre and South 
of Italy joined the study. Among these, there are some 
large COVID units. Others are pneumology units, 
mainly coordinated by pneumologists belonging to the 
SITAB. Home dwellings of confirmed COVID-19 
patients in selected territorial realities (e.g., centers of 
Tuscany and S. Marino) will be enrolled in the study 
too.
Patients 
COSMO-IT will enroll, either retrospectively 
(from March to July 2020) or prospectively according 
to the approval dates of the  various Ethics Commit-
tees, all consecutive, laboratory-confirmed COVID-19 
patients admitted to the wards of the participating 
hospitals. Also, an opportunistic sample of consecu-
tive, laboratory confirmed, COVID-19 patients iso-
lated at their home, identified and followed by selected 
territorial realities on the same period will be enrolled 
in the study. 
Experimental design 
For research aim 1, the enrolled patients will be 
followed from the date at hospitalization to the date at 
discharge (or death). A “severe clinical course”, defined 
as hospitalization in an intensive care unit, the need for 
mechanical ventilation or death versus a “mild clinical 
course”, defined as use of oxygen or Continuous Posi-
tive Airway Pressure (CPAP) will be considered as a 
primary endpoint. The analysis of the data collected 
for this aim will allow to quantify the association be-
tween cigarette smoking and risk of severe versus mild 
clinical course of patients hospitalized for COVID-19. 
Moreover, the analysis of the association between time 
since stopping versus current smoking will enable the 
investigation of the effect of smoking cessation on 
COVID-19 severity and progression.
For research aim 2, COVID-19 patients with a 
disease confirmed by positive swab, who were isolated 
at their home, and identified in selected territorial re-
alities will be enrolled. They will presumably have a 
milder clinical course and less serious symptoms com-
pared with hospitalized patients. Similar set of data as 
those collected for hospitalized patients will be collect-
ed also for these patients. Comparing the two popula-
tions of patients in terms of smoking prevalence, we 
will be able to understand the role of tobacco smoking 
on hospitalization for COVID-19.
In the longitudinal study conducted in hospital 
centers, information will also be collected on some 
lifestyle habits for research aim 3. This study will allow 
us to quantify the association between these potential 
risk factors and the risk of severe COVID-19 clinical 
course.
Data collection 
For each patient enrolled in the study (either 
hospitalized or isolated at home), data on socio-
demographic characteristics, major pre-existing 
chronic conditions and prior use of selected drugs 
will be collected. In particular, information will be 
gathered on anthropometric characteristics (cur-
rent self-reported weight and height) and selected 
lifestyle habits, including tobacco smoking (e.g., 
smoking status, and, for former smokers, time since 
stopping), e-cigarette and HTP use, and consump-
tion of alcoholic beverages at the time of hospitali-
zation or isolation at home. Also, information on 
COVID-19 symptoms, onset date and severity of 
the disease will also be collected. For hospitalized 
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patients, information will be collected on the type 
of hospitalization, type of therapy, prescribed drugs 
and possible complications during hospitalization. 
For patients isolated at home, relevant information 
of the clinical course will be collected. At the end of 
the hospitalization (or the end of the clinical course 
for patients in home isolation), the outcome will be 
recorded (i.e., discharge or laboratory confirmed re-
covery, any transfer and death).
Baseline and follow-up information will be 
 collected prospectively, for new patients, or retrospec-
tively for previously hospitalized or isolated patients 
extracting data already available on the patient’s medi-
cal records or by contacting patients (or relatives, in 
the case of deceased patients) to collect missing infor-
mation. All data will be collected through an electronic 
data collection form by the researchers at each center, 
and provided anonymously to the IRFMN, where data 
will be managed in accordance with the current Euro-
pean privacy laws.
Statistical analysis 
Data will be summarized through appropriate 
descriptive statistics. Analyses of main and secondary 
outcomes will be done through multivariable analyses. 
In particular, logistic regression models will be used 
to quantify the association between selected potential 
risk factors and the risk of COVID-19 severity and 
prognosis, after allowance for several covariates, in-
cluding sex, age and prior comorbidities.
Sample size 
As a primary endpoint, we will consider a “severe 
clinical course” (defined as hospitalization in an inten-
sive care unit, the need for mechanical ventilation or 
death) versus a “mild clinical course” (defined as use 
of oxygen or CPAP). An average of 100 patients are 
expected to be enrolled in each of the 33 Italian hospi-
tal centers. Assuming a smoking prevalence among pa-
tients with a mild clinical course of 20%, a sample size 
of 3000 COVID-19 patients (including about 15% 
with a severe clinical course) will allow to appreciate 
a significant odds ratio (OR) for smokers versus non-
smokers of at least 1.35, with alpha = 0.05 and power 
= 0.80. For the group of COVID-19 patients isolated 
at their home and enrolled by the territorial units, a 
sample size of about 700-1000 patients is expected to 
participate in the study.
Coordination centers
IRFMN and ISPRO will be the coordination 
centers.
Ethical aspects
This study protocol has been approved by the 
ISPRO Ethics Committee on June the 6th 2020 (N. 
17495), which acts as the Coordinator of Ethical Is-
sues. It has now been submitted to the Ethics Com-
mittee of each data collection center. Each patient will 
receive all the details of the study and will be contacted 
to give an informed consent. In case of deceased pa-
tients, the informed consent will be asked to a familiar 
or close relative. 
Limitations
One of the main problems is the long period of 
time needed to deal with the ethical aspects of each of 
the participating hospitals.
Another problem concerns the possibility that 
not all the information on the lifestyle habits will be 
available from the medical records. For this reason, we 
planned to contact patients and interview them about 
their lifestyles. This can lead to some difficulties, par-
ticularly for deceased people; in this case, informed 
consent and missing data will be requested to a family 
member or close relative.
Significance and Innovation 
This project is designed to highly contribute to 
the international scientific debate on the role of life-
style habits on COVID-19 severity. Indeed, scientific 
knowledge on the possible role of major risk factors 
(including tobacco, HTP, obesity and alcohol) on 
COVID-19 outcomes is still limited. 
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The present study, the first in Italy based on a 
large multicenter sample, will be able to quantify the 
association between several avoidable lifestyles and 
the risk of complications in COVID-19 prognosis. 
These findings will have significant implications from 
a public health perspective and a substantial impact on 
the National Health System, particularly in the cur-
rent absence of a vaccine or an effective treatment for 
COVID-19 because they will provide correct recom-
mendations to prevent COVID-19 incidence, progres-
sion and mortality. The findings of this study will be 
disseminated via peer-reviewed publications and pres-
entations at national and international conferences.
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APPENDIX: The COSMO-IT Investigators 
Ancona, Ospedali Riuniti di Torrette di  Ancona (Federico 
Giulietti, Riccardo Sarzani, Francesco Spannella)
Benevento, AORN “S.Pio”- P.O. “G.Rummo” (Mario Del 
Donno, Stefania Tartaglione)
Catanzaro, Policlinico Universitario Magna Graecia, AO 
Mater Domini (Giuseppina Marrazzo, Girolamo Pelaia)
Eboli (SA), Ospedale Eboli (Vincenzo D’Agosto)
Firenze, ARS Toscana (Alice Berti, Fabio Voller)
Firenze, Azienda Ospedaliera Universitaria Careggi (Sal-
vatore Cardellicchio, Chiara Cresci)
Firenze, Istituto per lo Studio, la Prevenzione, e la Rete 
Oncologica (Giulia Carreras, Giuseppe Gorini)
Foggia, Policlinico Riuniti (Maria Pia Foschino Barbaro)
Genova, Policlinico S. Martino (Raffaele De Palma, Si-
mone Negrini, Vera Sicbaldi)
Imperia, Ospedale di Imperia, ASL 1 Imperiese (An-
tonella Serafini)
Lecce, Ospedale Vito Fazzi (Mario Bisconti, Leonida Re-
folo)
Milano, Fondazione IRCCS Istituto Nazionale dei Tu-
mori (Roberto Boffi, Chiara Veronese)
Milano, Istituto di Ricerche Farmacologiche Mario Ne-
gri IRCCS (Cristina Bosetti, Silvano  Gallus, Alessandra Lugo, 
Claudia Santucci, Chiara Stival)
Milano, Ospedale San Raffaele (Giovanni Landoni, Patri-
zia Rovere, Giulia Veronesi)
Monza, Ospedale San Gerardo (Paola Faverio, Werner 
Garavello, Alberto Pesci)
Napoli, A.O.R.N. A. Cardarelli (Raffaella Giacobbe, Pao-
la Martucci)
Napoli, Ospedale Domenico Cotugno (Roberto Parrella, 
Francesco Scarano)
Parma, Azienda Ospedaliero Universitaria di Parma (Ma-
rina Aiello, Alfredo Chetta)
Piacenza, Ospedale Guglielmo da Saliceto (Cosimo Fran-
co, Angelo Mangia)
Pisa, Azienda Ospedaliero-Universitaria Pisana (Laura 
Carrozzi, Fabrizio Maggi, Fabio Monzani, Francesco Pistelli, 
Patrizia Russo)
Pistoia, Ospedale San Jacopo, Azienda USL Toscana 
Centro (Antonio Sanna)
Reggio Calabria, Grande Ospedale Metropolitano (Filip-
po Maria Barreca)
Repubblica di San Marino, Ospedale di Stato (Valentina 
Conti, Enrico Rossi, Mei Ruli, Silvana Ruli)
Rieti, Ospedale S. Camillo De Lellis (Shokoofe Eslami 
Varzaneh)
Roma, Istituto Superiore di Sanità (Roberta  Pacifici)
Roma, Azienda Ospedaliera San Camillo Forlanini 
(Rosastella Principe, Simone Guerrini, Alfredo Sebastiani, 
Giovanni Galluccio)
Roma, Azienda Ospedaliero-Universitaria Sant’Andrea 
(Aldo Pezzuto, Alberto Ricci)
Roma, Azienda Ospedaliero-Universitaria Policlinico 
Umberto I (Elena Casali, Claudio Mastroianni)
Roma, La Sapienza Università di Roma (Maria Sofia Cat-
taruzza)
Sassari, Azienda Ospedaliero Universitaria di Sassari (Pi-
etro Pirina, Francesca Polo)
SITAB Società Italiana di Tabaccologia, Italy (Vincenzo 
Zagà)
Torino, Ospedale San Giovanni Bosco, ASL Città di To-
rino (Fabio Beatrice)
Treviso, Ospedale Cà Foncello, ULSS 2 (Micaela Romag-
noli)
Udine, Azienza Sanitaria Universitaria Friuli Centrale 
(Massimo Baraldo, Pier Giorgio Cojutti, Elena Graziano, Da-
vide Pecori, Carlo Tascini)
Vimercate (MB), ASST Vimercate (Biagio Tinghino)
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